Skip to main content

Table 4 Doubling of sex steroids and SHBG and breast cancer risk: Nurses' Health Study II, 1999 to 2009

From: Premenopausal endogenous steroid hormones and breast cancer risk: results from the Nurses' Health Study II

 

All Cases*

Premenopausal at Diagnosis

Postmenopausal at Diagnosis

P het**

 

cases/

 

cases/

 

cases/

  
 

controls

OR (95% CI)

controls

OR (95% CI)

controls

OR (95% CI)

 

FOLLICULAR

       

Estradiol

       

   All cancers

462/909

1.0 (0.9 to 1.2)

340/677

1.1 (0.9 to 1.3)

92/176

0.6 (0.4 to 0.9)

< 0.01

   Invasive

299/909

1.0 (0.9 to 1.2)

221/677

1.2 (1.0 to 1.4)

62/176

0.6 (0.4 to 0.9)

< 0.01

   ER+/PR+

201/909

1.0 (0.8 to 1.2)

152/677

1.2 (0.9 to 1.5)

43/176

0.6 (0.4 to 0.9)

0.01

Free Estradiol

       

   All cancers

447/886

1.0 (0.8 to 1.1)

330/668

1.1 (0.9 to 1.4)

86/162

0.5 (0.4 to 0.8)

< 0.01

   Invasive

288/886

0.9 (0.8 to 1.1)

214/668

1.2 (0.9 to 1.5)

57/162

0.5 (0.3 to 0.7)

< 0.01

   ER+/PR+

194/886

0.9 (0.8 to 1.1)

146/668

1.2 (0.9 to 1.5)

41/162

0.4 (0.3 to 0.7)

< 0.01

Estrone

       

   All cancers

469/920

1.0 (0.8 to 1.3)

347/692

1.0 (0.8 to 1.3)

91/173

1.0 (0.6 to 1.7)

0.83

   Invasive

305/920

1.0 (0.8 to 1.2)

227/692

0.9 (0.7 to 1.3)

61/173

0.8 (0.5 to 1.4)

0.85

   ER+/PR+

206/920

1.2 (0.9 to 1.5)

156/692

1.1 (0.8 to 1.6)

43/173

1.0 (0.6 to 1.8)

0.95

LUTEAL

       

Estradiol

       

   All cancers

479/959

1.0 (0.8 to 1.2)

347/710

1.0 (0.8 to 1.3)

98/190

1.1 (0.7 to 1.7)

0.82

   Invasive

316/959

1.2 (1.0 to 1.4)

232/710

1.2 (1.0 to 1.6)

67/190

1.1 (0.7 to 1.7)

0.66

   ER+/PR+

215/959

1.2 (1.0 to 1.5)

162/710

1.3 (1.0 to 1.8)

47/190

1.2 (0.8 to 2.1)

0.80

Free estradiol

       

   All cancers

469/944

1.0 (0.8 to 1.2)

339/702

1.0 (0.8 to 1.3)

96/183

1.1 (0.7 to 1.7)

0.61

   Invasive

309/944

1.1 (0.9 to 1.4)

227/702

1.2 (0.9 to 1.5)

65/183

1.0 (0.7 to 1.7)

0.52

   ER+/PR+

209/944

1.2 (0.9 to 1.5)

157/702

1.2 (0.9 to 1.7)

46/183

1.3 (0.8 to 2.3)

0.88

Estrone

       

   All cancers

500/1005

1.0 (0.8 to 1.2)

366/751

0.9 (0.7 to 1.2)

99/194

1.3 (0.8 to 2.1)

0.22

   Invasive

328/1005

1.1 (0.9 to 1.4)

242/751

1.0 (0.8 to 1.3)

67/194

1.4 (0.8 to 2.2)

0.34

   ER+/PR+

221/1005

1.1 (0.8 to 1.4)

167/751

1.0 (0.7 to 1.4)

47/194

1.5 (0.9 to 2.7)

0.26

Progesterone

       

   All cancers

501/1009

1.0 (0.9 to 1.1)

368/753

1.0 (0.9 to 1.2)

96/193

0.9 (0.7 to 1.1)

0.24

   Invasive

329/1009

1.0 (0.9 to 1.1)

243/753

1.1 (0.9 to 1.2)

66/193

0.8 (0.7 to 1.0)

0.29

   ER+/PR+

222/1009

1.0 (0.9 to 1.1)

168/753

1.0 (0.9 to 1.2)

46/193

0.8 (0.6 to 1.0)

0.42

LUTEAL AND UNTIMED

       

Testosterone

       

   All cancers

623/1245

1.2 (1.0 to 1.4)

417/858

1.1 (0.9 to 1.4)

141/271

1.3 (0.8 to 2.0)

0.52

   Invasive

421/1245

1.2 (1.0 to 1.5)

278/858

1.1 (0.8 to 1.4)

100/271

1.8 (1.1 to 2.8)

0.16

   ER+/PR+

290/1245

1.3 (1.0 to 1.7)

192/858

1.2 (0.9 to 1.7)

70/271

1.9 (1.1 to 3.4)

0.41

Free testosterone

       

   All cancers

617/1237

1.0 (0.9 to 1.1)

414/853

1.0 (0.8 to 1.2)

138/267

1.2 (0.8 to 1.8)

0.23

   Invasive

416/1237

1.0 (0.8 to 1.2)

276/853

0.9 (0.7 to 1.1)

97/267

1.3 (0.9 to 1.9)

0.24

   ER+/PR+

287/1237

1.1 (0.9 to 1.3)

190/853

1.0 (0.8 to 1.3)

69/267

1.7 (1.0 to 2.6)

0.22

DHEAS

       

   All cancers

628/1254

1.1 (1.0 to 1.2)

422/861

1.1 (0.9 to 1.2)

141/276

1.1 (0.8 to 1.4)

0.71

   Invasive

423/1254

1.1 (0.9 to 1.2)

280/861

1.0 (0.9 to 1.2)

100/276

1.1 (0.8 to 1.5)

0.38

   ER+/PR+

291/1254

1.2 (1.0 to 1.4)

193/861

1.1 (0.9 to 1.4)

70/276

1.3 (0.9 to 1.9)

0.22

SHBG

       

   All cancers

624/1246

1.1 (1.0 to 1.3)

421/859

1.2 (1.0 to 1.4)

138/270

0.9 (0.7 to 1.4)

0.27

   Invasive

420/1246

1.2 (1.0 to 1.4)

280/859

1.2 (1.0 to 1.5)

97/270

1.0 (0.7 to 1.5)

0.66

   ER+/PR+

290/1246

1.1 (0.9 to 1.3)

193/859

1.2 (0.9 to 1.5)

69/270

0.9 (0.6 to 1.3)

0.37

  1. *Includes women of all menopausal statuses at diagnosis (premenopausal, postmenopausal and unknown). **Phet represents heterogeneity between premenopausal vs. postmenopausal status at diagnosis, among women premenopausal at blood collection. All cancers: Conditional logistic regression for all cancers controlling for age at menarche, parity/age at first birth, BMI at age 18, family history of breast cancer, history of benign breast disease. Invasive, ER+/PR+ tumors: Unconditional logistic regression for invasive and ER+/PR+ disease controlling for factors listed above and matching factors.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us